FDA unable to conclude QRxPharma's MoxDuo has safety benefit
This article was originally published in Scrip
Executive Summary
FDA drug reviewers have been unable to conclude there is a safety benefit with QRxPharma's fixed-ratio, immediate-release combination morphine sulfate and oxycodone hydrochloride product MoxDuo over its individual components, the agency said in briefing documents posted on its website on 18 April.